CIK 0000727207
AXDX Accelerate Diagnostics, Inc
Insider trading from SEC Form 4. Last filing Apr 7, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at Accelerate Diagnostics, Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Larry Michael Mertz Chief Technology Officer sell | $990 1,523 shares | -2% | - | |
| 30Weak | Jack Phillips Chief Executive Officer sell | $16k 25,343 shares | -12% | - | |
| 22Weak | David Patience Chief Financial Officer sell | $4,839 6,816 shares | -10% | - | |
| 7Weak | David Patience Chief Financial Officer sell | $583 535 shares | -1% | - | |
| 10Weak | Jack Phillips Chief Executive Officer sell | $655 485 shares | -0% | - | |
| 29Weak | Jack W Schuler director, owner sell | $314k 200,000 shares | -2% | - | |
| 35Weak | John Patience director buy | $314k 200,000 shares | +44% | - |
Transactions
The last 17 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 4, 2025 | Jack Phillips Chief Executive Officer | MOption exercise Common Stock | +53,283 | $0.00 | $0 | 216,717 | Apr 7, 2025 |
| Apr 4, 2025 | Larry Michael Mertz Chief Technology Officer | MOption exercise Common Stock | +4,298 | $0.00 | $0 | 86,326 | Apr 7, 2025 |
| Apr 4, 2025 | Larry Michael Mertz Chief Technology Officer | SOpen-market sale Common Stock | -1,523 | $0.65 | $990 | 84,803 | Apr 7, 2025 |
| Apr 4, 2025 | Jack Phillips Chief Executive Officer | SOpen-market sale Common Stock | -25,343 | $0.65 | $16k | 191,374 | Apr 7, 2025 |
| Apr 4, 2025 | Larry Michael Mertz Chief Technology Officer | MOption exercise Employee Restricted Stock Unitsderivative | -4,298 | $0.00 | $0 | 0 | Apr 7, 2025 |
| Apr 4, 2025 | Jack Phillips Chief Executive Officer | MOption exercise Employee Restricted Stock Unitsderivative | -53,283 | $0.00 | $0 | 0 | Apr 7, 2025 |
| Apr 1, 2025 | David Patience Chief Financial Officer | MOption exercise Common Stock | +20,000 | $0.00 | $0 | 71,384 | Apr 2, 2025 |
| Apr 1, 2025 | David Patience Chief Financial Officer | SOpen-market sale Common Stock | -6,816 | $0.71 | $4,839 | 64,568 | Apr 2, 2025 |
| Apr 1, 2025 | David Patience Chief Financial Officer | MOption exercise Employee Restricted Stock Unitsderivative | -20,000 | $0.00 | $0 | 30,000 | Apr 2, 2025 |
| Feb 26, 2025 | David Patience Chief Financial Officer | MOption exercise Common Stock | +1,500 | $0.00 | $0 | 51,919 | Feb 27, 2025 |
| Feb 26, 2025 | David Patience Chief Financial Officer | SOpen-market sale Common Stock | -535 | $1.09 | $583 | 51,384 | Feb 27, 2025 |
| Feb 26, 2025 | David Patience Chief Financial Officer | MOption exercise Employee Restricted Stock Unitsderivative | -1,500 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 1, 2025 | Jack Phillips Chief Executive Officer | MOption exercise Common Stock | +1,000 | $0.00 | $0 | 163,919 | Feb 4, 2025 |
| Feb 3, 2025 | Jack Phillips Chief Executive Officer | SOpen-market sale Common Stock | -485 | $1.35 | $655 | 163,434 | Feb 4, 2025 |
| Feb 1, 2025 | Jack Phillips Chief Executive Officer | MOption exercise Employee Restricted Stock Unitsderivative | -1,000 | $0.00 | $0 | 0 | Feb 4, 2025 |
| Dec 3, 2024 | Jack W Schuler director, owner | SOpen-market sale Common Stockindirect: By Jack W. Schuler Living Trust | -200,000 | $1.57 | $314k | 8,310,388 | Dec 3, 2024 |
| Dec 3, 2024 | John Patience director | POpen-market purchase Common Stockindirect: By John Patience Living Trust dated 7/23/1993 | +200,000 | $1.57 | $314k | 653,224 | Dec 3, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Larry Michael MertzChief Technology Officer
- John Patiencedirector, other
- David PatienceChief Financial Officer
- Jack PhillipsChief Executive Officer
- Jack W Schulerdirector, owner, other
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.